Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

  • Thol F
  • Friesen I
  • Damm F
 et al. 
  • 38

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

PURPOSE: To study the incidence and prognostic impact of mutations in Additional sex comb-like 1 (ASXL1) in a large cohort of patients with myelodysplastic syndrome (MDS).

PATIENTS, MATERIALS, AND METHODS: Overall, 193 patients with MDS and 65 healthy volunteers were examined for ASXL1 mutations by direct sequencing and for expression levels of ASXL1. The prognostic impact of ASXL1 mutation and expression levels was evaluated in the context of other clinical and molecular prognostic markers.

RESULTS: Mutations in ASXL1 occurred with a frequency of 20.7% in MDS (n = 40 of 193) with 70% (n = 28) of mutations being frameshift mutations and 30% (n = 12) being heterozygous point mutations leading to translational changes. ASXL1 mutations were correlated with an intermediate-risk karyotype (P = .002) but not with other clinical parameters. The presence of ASXL1 mutations was associated with a shorter overall survival for frameshift and point mutations combined (hazard ratio [HR], 1.744; 95% CI, 1.08 to 2.82; P = .024) and for frameshift mutations only (HR, 2.06; 95% CI, 1.21 to 3.50; P = .008). ASXL1 frameshift mutations were associated with a reduced time to progression of acute myeloid leukemia (AML; HR 2.35; 95% CI, 1.17 to 4.74; P = .017). In multivariate analysis, when considering karyotype, transfusion dependence, and IDH1 mutation status, ASXL1 frameshift mutations remained an independent prognostic marker in MDS (overall survival: HR, 1.85; 95% CI, 1.03 to 3.34; P = .040; time to AML progression: HR, 2.39; 95% CI, 1.12 to 5.09; P = .024).

CONCLUSION: These results suggest that ASXL1 mutations are frequent molecular aberrations in MDS that predict an adverse prognostic outcome. Screening of patients for ASXL1 mutations might be useful for clinical risk stratification and treatment decisions in the future.

Author-supplied keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antilymphocyte Serum
  • Biological Markers
  • Clinical Trials as Topic
  • Clinical Trials as Topic: statistics & numerical d
  • DNA Methylation
  • DNA Mutational Analysis
  • Disease Progression
  • Exons
  • Exons: genetics
  • Female
  • Follow-Up Studies
  • Frameshift Mutation
  • Gene Expression Profiling
  • Genes, MHC Class II
  • Humans
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid, Acute: epidemiology
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Multicenter Studies as Topic: statistics & numeric
  • Myelodysplastic Syndromes
  • Myelodysplastic Syndromes: genetics
  • Myelodysplastic Syndromes: mortality
  • Myelodysplastic Syndromes: therapy
  • Point Mutation
  • Prognosis
  • Proportional Hazards Models
  • RNA, Messenger
  • RNA, Messenger: biosynthesis
  • Repressor Proteins
  • Repressor Proteins: analysis
  • Repressor Proteins: biosynthesis
  • Repressor Proteins: genetics
  • Risk

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Felicitas Thol

  • Inna Friesen

  • Frederik Damm

  • Haiyang Yun

  • Eva M Weissinger

  • Jürgen Krauter

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free